Qualcomm Incorporated (NASDAQ: QCOM), through its subsidiary Qualcomm Life, Inc., today announced its collaboration with PAREXEL International Corporation (NASDAQ: PRXL) to expand PAREXEL’s clinical technology service offerings to include a connected sensor platform to digitize clinical trials. PAREXEL, a leading biopharmaceutical services company, is leveraging Qualcomm Life’s 2net™ medical-grade solution and ecosystem of integrated medical devices in its recently launched Patient Sensor Solution, an end-to-end services and technology solution that facilitates the remote collection of study subject data via medical devices.
“Companies across the life science industry are increasingly looking for ways to conduct clinical trials more effectively and efficiently by incorporating alternative data solutions to better meet today’s evolving regulatory and payer standards,” said Xavier Flinois, President, PAREXEL Informatics. “Qualcomm Life’s 2net connectivity solution and ecosystem of integrated medical devices provides our Patient Sensor Solution with the secure infrastructure needed to deliver greater efficiencies for sponsors, allowing them to generate clinical and quality-of-life endpoints via medical devices and distinguish treatments from competition through remote monitoring.”
PAREXEL is leveraging Qualcomm Life’s platform to securely capture, transmit, store, and visualize patient data during clinical trials. With this platform, PAREXEL aims to improve the accuracy and timeliness of data collection to maximize efficiencies, reduce costs, and gain a more holistic view of trial participants’ health. Qualcomm Life’s 2net Quality Management System is based on FDA and EU-MDD regulations, and is ISO 13485:2003 certified and designed to HIPAA privacy and security standards.
“We are honored to be working with PAREXEL, a global leader in clinical development solutions, to provide connectivity capabilities to its clinical trial platform,” said Rick Valencia, president, Qualcomm Life. “Through this collaboration, we aim to help PAREXEL in streamlining clinical trials to improve accuracies, create efficiencies for clinicians and trial participants, enabling more timely, informed care.”
About Qualcomm Incorporated
Qualcomm Incorporated (NASDAQ: QCOM) is a world leader in 3G, 4G and next-generation wireless technologies. Qualcomm Incorporated includes Qualcomm’s licensing business, QTL, and the vast majority of its patent portfolio. Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, substantially all of Qualcomm’s engineering, research and development functions, and substantially all of its products and services businesses, including its semiconductor business, QCT. For more than 30 years, Qualcomm ideas and inventions have driven the evolution of digital communications, linking people everywhere more closely to information, entertainment and each other. For more information, visit Qualcomm’s website, OnQ blog, Twitter and Facebook pages.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has 86 locations in 51 countries around the world, and had approximately 19,370 employees in the third quarter. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.